DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Liver Cirrhosis - Pipeline Review, H2 2016" report to their offering.
Liver Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.
Liver Cirrhosis pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Liver Cirrhosis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Liver Cirrhosis Overview
- Therapeutics Development
- Pipeline Products for Liver Cirrhosis - Overview
- Pipeline Products for Liver Cirrhosis - Comparative Analysis
- Liver Cirrhosis - Therapeutics under Development by Companies
- Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
- Liver Cirrhosis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Liver Cirrhosis - Products under Development by Companies
- Liver Cirrhosis - Products under Investigation by Universities/Institutes
- Liver Cirrhosis - Companies Involved in Therapeutics Development
- Conatus Pharmaceuticals Inc.
- Digna Biotech, S.L.
- Galectin Therapeutics, Inc.
- Human Stem Cells Institute
- Nimbus Therapeutics, LLC
- Ocera Therapeutics, Inc.
- Pharmicell Co., Ltd.
- S-Evans Biosciences, Inc.
- Stelic Institute & Co., Inc.
For more information about this report visit http://www.researchandmarkets.com/research/v7dhbp/liver_cirrhosis
